Online inquiry

IVTScrip™ mRNA-Anti-DPEP3, SC-003 mAb(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14659MR)

This product GTTS-WQ14659MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets DPEP3 gene. The antibody can be applied in Ovarian Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001129758.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 64180
UniProt ID Q9H4B8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-DPEP3, SC-003 mAb(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ14659MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3335MR IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AT-001
GTTS-WQ15511MR IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA UCB-7665
GTTS-WQ13732MR IVTScrip™ mRNA-Anti-ERBB2, RC48-0(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA RC48-0
GTTS-WQ495MR IVTScrip™ mRNA-Anti-IGHE, 47H4(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 47H4
GTTS-WQ7615MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA G-CSF-Fc-PEG
GTTS-WQ4443MR IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-734016
GTTS-WQ12781MR IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA OMP-59R5
GTTS-WQ1813MR IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AFD Anti-fD
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW